BioPharmaTrend
Latest Insights
Companies
  • Companies Directory
  • Case Studies
Newsletter
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
 
 Subscribe 
Sign in
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Business Intelligence
Back to Companies Directory

Evid Science (acquired by Genesis Research)

Evid Science logo

Website
https://evidscience.com/
Founded
2017

Technologies

AI Companies (Drug Discovery)

Evid Science represents a revolution in the healthcare and pharmaceutical industries. Leveraging cutting edge research in Artificial Intelligence and Machine Learning, we are building the largest database of therapy evidence in the world. Soon, the answers to any comparative cost and outcomes questions will be answerable, in milliseconds.

Backed by years of research and multiple pending patents, our Artificial Intelligence technology generates evidence by ingesting the entire primary literature of peer-reviewed articles and pulling out the salient data points, at a rate thousands of times faster than a human. It then blends these results across innumerable combinations to generate customized summaries of the cost and outcomes data, in seconds.

data analysis data visualization

R&D Platform

Our Artificial Intelligence technology generates evidence by ingesting the entire primary literature of peer-reviewed articles and pulling out the salient data points.

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Press & Citations
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Disclaimer

Topics


  • News
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures

Explore


  • Premium Insights
  • Business Intelligence
  • Companies
  • Events
  • Authors

Partner


  • Sponsorship
  • Editorial Calendar

© WTMB Research & Media, S.L. (WTMB Group)   2026
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.